The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
 
Lin Shen
No Relationships to Disclose
 
Ye Guo
Honoraria - BMS; Merck Serono; MSD; Roche
Consulting or Advisory Role - Bayer; Merck Serono; MSD; Roche
 
Yanqiao Zhang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Qun Li
No Relationships to Disclose
 
Zhigang Ma
No Relationships to Disclose
 
Nanya Wang
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Consulting or Advisory Role - Bayer; Merck Serono; MSD; Roche
 
Rila Su
Employment - CStone Pharmaceuticals
 
Zhongheng Cai
Employment - CStone Pharmaceuticals
 
Rong Guo
Employment - CStone Pharmaceuticals
 
Peiqi Li
Employment - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
Travel, Accommodations, Expenses - CStone Pharmaceuticals
 
Archie N. Tse
Employment - CStone Pharmaceuticals
Leadership - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
Patents, Royalties, Other Intellectual Property - One of the inventors in patents while employed at Merck & Co.